Rituximab

Drug #1655

Rituximab is a monoclonal antibody which causes lysis of B-lymphocytes. Rituximab is used for the treatment of chemotherapy-resistant advanced follicular lymphoma, breast cancer and for diffuse large B-cell non-hodgkin`s lymphoma in combination with other chemotherapy.

← Previous drug Next drug →

Primary Characteristics

It is of Natural origin.

Non-proprietary name: Rituximab.

Pharmacokinetics

None recorded.

Indications

Rituximab is primarily indicated in conditions like Advanced follicular lymphoma(chemo resistant), Non-hodgkin's lymphoma.

Rituximab is also indicated for secondary conditions like Sedation with amnesia.

Contraindications

Rituximab is contraindicated in conditions like Breast feeding, Hypersensitivity to any component of product, Hypersensitivity to murine proteins.

Dosage

Rituximab's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
375 mg/m2	375 mg/m2	—	IV-Inf	Once weekly for 4 doses.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

4 interactions

Major5 interactions

Moderate1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Rituximab is known to cause more or less tolerable side effects which are usually transient. These include Affectced liver function, Blood dyscrasias.

Warnings / Precautions

Pregnancy. Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion.

Available Brands

None recorded.

Storage Conditions

Rituximab should be stored Inj.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs